2. Academic Validation
  3. Novel Fredericamycin Variant Overproduced by a Streptomycin-resistant Streptomyces albus subsp. chlorinus Strain

Novel Fredericamycin Variant Overproduced by a Streptomycin-resistant Streptomyces albus subsp. chlorinus Strain

  • Mar Drugs. 2020 May 28;18(6):284. doi: 10.3390/md18060284.
Marta Rodríguez Estévez 1,  Maksym Myronovskyi 1,  Birgit Rosenkränzer 1,  Thomas Paululat 2,  Lutz Petzke 3,  Jeanette Ristau 3,  Andriy Luzhetskyy 1 4
Affiliations

Affiliations

  • 1 Pharmazeutische Biotechnologie, Universität des Saarlandes, 66123 Saarbrücken, Germany.
  • 2 Organische Chemie II, Universität Siegen, 57068 Siegen, Germany.
  • 3 BASF SE, 67056 Ludwigshafen, Germany.
  • 4 Helmholtz-Institut für Pharmazeutische Forschung Saarland, 66123 Saarbrücken, Germany.
PMID: 32481766 DOI: 10.3390/md18060284
Abstract

Streptomycetes are an important source of Natural Products potentially applicable in the pharmaceutical industry. Many of these drugs are secondary metabolites whose biosynthetic genes are very often poorly expressed under laboratory cultivation conditions. In many cases, antibiotic-resistant mutants exhibit increased production of natural drugs, which facilitates the identification and isolation of new substances. In this study, we report the induction of a type II polyketide synthase gene cluster in the marine strain Streptomyces albus subsp. chlorinus through the selection of streptomycin-resistant mutants, resulting in overproduction of the novel compound fredericamycin C2 (1). Fredericamycin C2 (1) is structurally related to the potent antitumor drug lead fredericamycin A.

Keywords

antitumor; fredericamycin; overproduction; secondary metabolites; streptomycetes; streptomycin-resistant; type II PKS.

Figures
Products